Delcath Systems (NASDAQ:DCTH) Downgraded to “Sell” at StockNews.com

StockNews.com lowered shares of Delcath Systems (NASDAQ:DCTH) from a hold rating to a sell rating in a research note released on Thursday.

A number of other equities research analysts also recently weighed in on DCTH. HC Wainwright restated a buy rating and issued a $22.00 price target on shares of Delcath Systems in a research note on Tuesday, August 6th. Craig Hallum started coverage on shares of Delcath Systems in a research report on Friday, June 28th. They issued a buy rating and a $18.00 target price on the stock. Finally, Stephens reiterated an overweight rating and set a $25.00 price target on shares of Delcath Systems in a report on Tuesday, August 6th.

Delcath Systems Price Performance

NASDAQ DCTH opened at $9.00 on Thursday. The business has a fifty day moving average price of $8.81 and a two-hundred day moving average price of $7.08. The stock has a market capitalization of $250.07 million, a PE ratio of -3.40 and a beta of 0.78. Delcath Systems has a fifty-two week low of $2.25 and a fifty-two week high of $11.74.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12). The business had revenue of $7.77 million for the quarter, compared to analyst estimates of $5.00 million. Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. During the same period last year, the firm posted ($0.58) EPS. As a group, sell-side analysts expect that Delcath Systems will post -1.67 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Levin Capital Strategies L.P. grew its holdings in Delcath Systems by 12.2% during the 1st quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock worth $262,000 after acquiring an additional 5,969 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Delcath Systems in the second quarter worth $370,000. Renaissance Technologies LLC bought a new stake in shares of Delcath Systems in the second quarter worth $694,000. Marshall Wace LLP increased its holdings in Delcath Systems by 7.0% in the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock valued at $776,000 after purchasing an additional 6,066 shares during the period. Finally, ADAR1 Capital Management LLC bought a new position in Delcath Systems during the 4th quarter worth $962,000. Institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.